Takeda Readying To Launch PPI Kapidex Within A Month
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Takeda expects to launch within a month its Kapidex (dexlansoprazole) delayed- release capsules for the treatment of gastroesophageal reflux disease, the same proton pump inhibitor class of drugs as its Prevacid, which is scheduled to lose patent protection this year, according to the company's third-quarter earnings call Feb. 3
You may also be interested in...
Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later
Takeda announced June 27 that U.S. FDA had denied approval of its type 2 diabetes agent alogliptin, a potential blockbuster poised to compete with similar molecules from Merck and the team of Bristol-Myers Squibb and AstraZeneca. The setback will delay alogliptin's launch by at least three years - and possibly longer - depending on the additional studies required by regulators
Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later
Takeda announced June 27 that U.S. FDA had denied approval of its type 2 diabetes agent alogliptin, a potential blockbuster poised to compete with similar molecules from Merck and the team of Bristol-Myers Squibb and AstraZeneca. The setback will delay alogliptin's launch by at least three years - and possibly longer - depending on the additional studies required by regulators
U.S. FDA Clears Takeda Uloric For Gout Indication
Despite concerns about cardiac safety, U.S. FDA approved Takeda's Uloric (febuxostat) for the chronic management of hyperuricemia in patients with gout Feb. 13. The approval marks the first new FDA-approved treatment for gout in more than 40 years